61085-72-1

Usage

Chemical Properties

Brown Oil

InChI:InChI=1/C23H28N2O3/c1-3-21(26)19-11-7-8-12-20(19)24-23(22(27)28-2)13-15-25(16-14-23)17-18-9-5-4-6-10-18/h4-12,24H,3,13-17H2,1-2H3

Upstream product

• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 1096-03-3 1-benzyl-4-phenylaminopiperidine-4-carboxylic acid amide 
• 85098-64-2 1-benzyl-4-(phenylamino)piperidine-4-carboxylic acid 
• 67-66-3 chloroform 
• 61085-60-7 methyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylate 
• 123-62-6 propionic acid anhydride 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 130819-94-2 1-benzyl-4-(propionanilido)piperidine-4-carbonitrile 
• 61085-47-0 sodium 4-carboxy-4-(phenylamino)-N-benzylpiperidine 
• 108-88-3 toluene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 256507-84-3 1-benzyl-4-[phenyl(propionyl)amino]piperidine-4-carboxylic acid 
• 62-53-3 aniline 

Downstream Products

• 61085-87-8 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-4-piperidinecarboxylate hydrochloride 
• 72996-78-2 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-4-piperidinecarboxylate 

Relevant academic research and scientific papers

FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING

This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

Alternate Process for Remifentanil Preparation

An alternate process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, a process of synthesizing synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed.

Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents

The synthesis, evaluation, and molecular modeling of a series of 18F-labeled 4-anilidopiperidines with high affinities for the μ-opioid receptor (μ-OR) are reported. On the basis of the high brain uptake and selective retention in brain regions that contain a high concentration of the μ-OR, combined with a good metabolic stability, [ 18F]fluoro-pentyl carfentanil ([18F]4) and 2-(±)[18F]-fluoropropyl-sufentanil ([18F]6) were selected as the lead compounds for further evaluation. The binding affinity to the human μ-OR was 0.74 and 0.13 nM for [18F]4 and [ 18F]6, respectively. In vitro autoradiography of [18F] 4 and [18F] 6 on rat brain sections produced patterns in accordance with the known distribution of μ-OR expression. Structure-activity relationships of the fluorinated compounds are discussed with respect to the interaction with an activated-state model of the μ-OR. Taken together, the in vivo and in vitro data indicate that [18F] 4 and [18F] 6 hold promise for studying the μ-opioid receptor in humans by means of positron emission tomography.

A convenient method for the N-acylation and esterification of hindered amino acids: Synthesis of ultra short acting opioid agonist, remifentanil

A general method has been devised for the one step preparation of N- acylamino acid esters of type 7 from the corresponding a-amino acids in high yield under mild conditions and a probable mechanism is proposed.

N-(4-piperidinyl)-N-phenylamides

Novel N-(4-piperidinyl)-N-phenylamides and -carbamates having very potent analgesic activity, methods of preparing same and useful intermediates therefor.

N-(4-piperidinyl)-N-phenylamides and -carbamates

Novel N-(4-piperidinyl)-N-phenylamides and -carbamates having very potent analgesic activity, methods of preparing same and useful intermediates therefor.